EBR Systems (ASX:EBR) is targeting an around $3.6 billion initial addressable market at the commercial launch of its Wireless Stimulation Endocardially (WiSE) Cardiac Resynchronisation Therapy (CRT) system, according to a Thursday Australian bourse filing.
The firm submitted its application to the US Centers for Medicare & Medicaid Services for the transitional pass-through reimbursement scheme for its proprietary WiSE CRT system.
The biggest segment in the initial addressable market is expected to be patients for whom the traditional CRT system implant has ceased to provide effective CRT. This segment represents $1.45 billion.
High-risk patients and patients with a leadless right ventricle pacemaker are also part of the firm's initial addressable market. Medtronic's Micra leadless pacemaker has been qualified for use with the WiSE CRT system.
The firm's shares slumped 12% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.